John Enrique Mata, Ph.D.
College of Osteopathic Medicine of the Pacific - Northwest
Phone: 541-259-0231 | Fax: 541-259-0201
Join year: 2011
Postdoctoral, Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon, 2003
Ph.D., Medical Sciences, University of Nebraska Medical Center, Omaha, Nebraska, 2000
B.S., Anthropology, University of Nebraska, Lincoln, Nebraska, 1983
Dr. Mata has academic interests beyond his focus on pharmacology that include a history of advocacy for women scientists in third world countries and support of minority researchers in science. He has been a member of the National Institute of Diabetes & Digestive & Kidney Diseases Network of Minority Research Investigators since 2003 and has served as a mentor through the Borlaug Fellowship Program. With a degree in Anthropology and an interest in poverty issues, Dr. Mata has been active in advocating for poverty issues and has previously sat on the board of directors of the Jackson Street Youth Shelter, the National Coalition for the Homeless, and the National Low Income Housing Coalition. He is a former director of the Omaha Coalition for the Homeless and a founder of the Nebraska Coalition for the Homeless. His advocacy also includes trips to Honduras and El Salvador to evaluate microenterprise loan programs.
Pharmacology I, Oregon State University, Corvallis, 2005-2010
Pharmacology II, Oregon State University, Corvallis, 2006-2010
Dr. Mata has spent the last 5 years serving as course coordinator for the pharmacology series presented to the second year veterinary students. In addition to coordinating the course, he taught the fundamentals of pharmocotherapy, pharmacokinetics, and pharmacology, worming agents, alternative veterinary medicine, and basic compounding. Dr. Mata also has experience in teaching antimicrobials, cardiovascular pharmacology, renal pharmacology, and cancer chemotherapy.
Dr. Mata's primary training has been in the field of pharmacology and he will be teaching the core pharmacology course involving introduction to pharmacology, antiobiotics, and pharmacokinetics.
Dr. Mata has several avenues of research interest that include:
Natural product research
• Understanding the role of dietary constituents on cancer prevention
• Use of natural dietary constituents to reduce cancer risk and improve health
• Natural product drug discovery
• Elucidation of active compounds from traditional medicines
• Pharmacokinetics of dietary constituents in humans
• Development of targeted peptides for tumor imaging and therapeutics
• Polynucleotide analogs for sustained delivery of active drugs to the lung
• Microwave technology for 3rd molar tooth bud ablation
Erkkila Foundation for Human Health and Performance (PI: Mata) 07/01/11-06/30/12
CT guided microwave ablation of third molar tooth bud in swine. This study will test the feasibility of using a small microwave ablation device to stop early tooth bud development. The goal of this project is to demonstrate in a swine model that it is possible to prevent the development of wisdom teeth in children. If successful this would lead to a new, less invasive treatment option for children at risk for third molar impaction and reduce the need for oral surgery.
Erkkila Foundation for Human Health and Performance (PI: Mata) 07/01/07-06/30/08
Cancer chemoprevention in smokers: a feasibility study. This study will measure the concentrations of cancer and smoking biomarkers using multiple methods of detection. The goal of the study is to determine the feasibility of measuring a 50% reduction in cancer biomarkers and determining the number of subjects required to observe a statistically significant reduction in risk.
HemCon, Inc. (PI: Mata) 10/01/05-07/31/09
Hemorrhage Control Bandage
This project is a research contract to characterize the systemic effects of implantation of chitosan based bandage formulations. Studies included subcutaneous implantation in rats and surgical placement of materials in swine liver.
NIH/NCI PO1 CA090890-02A2S1 (Director: Bailey, Co-I: Mata) 04/01/03-02/28/07
Comparative Mechanisms of Cancer Chemoprevention – Co-Investigator. This is a supplement to the parent grant NIH/NCI PO1 CA090890-02. Compare the mechanisms of cancer chemoprevention for CHL and Chla. Specifically, our focus on this project is testing the hypothesis that both agents protect primarily by reducing carcinogen bioavailability by acting as interceptor molecules.
USDA/SBIR 2004-00028 (PI: Hemingway, Collaborator: Mata) 05/01/04-04/30/05
Procyanidins made from Douglas-fir bark and tea leaves: Structure and Physiological Properties.
The focus of this project is the investigation of novel procaynidin effects on drug transporters on Caco-2 cells monolayers and cancer cell lines.
GeneTools, LLC (PI: Mata) 11/24/03-12/31/06
Characterization of Modified Phosphorothioate Oliomers (PMOs)
This project is a research contract to characterize novel peptides capable of carrying macromolecules into cells. The goal of this research is the delivery of pharmacologically active cancer agents and contrast agents to tumors in vivo.
DoD/USAMRMC BC032403 (PI: Mata) 08/15/04-08/14/06
Nanoprobe Directed Tumor Imaging pH Activated Peptides as Contrast Agent Carriers
The research is focused on the use of pH activated peptides conjugated to contrast agents that respond to the lower pH gradient found in tumors for diagnostic imaging in vivo.
Linus Pauling Institute (PI: Baird, Collaborator: Mata) 03/24/03-03/23/04
Oregon State University
Study of the effects of red raspberry extract on PAH transport across Calu-3 cell monolayers, and in vitro cell model.
Cancer chemoprevention by dietary phytochemicals found in red raspberries. Elucidation of active components by characterization of fractionated extracts on benzo(a)pyrene and dibenzo(a,l)pyrene transport and adduct formation in Calu-3 cells.
NIH Minority Graduate Fellowship, 1997-1998
Illustrator, CRC Desk Reference of Clinical Pharmacology, 1998
Ad-Hoc Reviewer, Toxicology in Vitro, 2002-present
Member, International Society for the Study of Xenobiotics, 2002-present
Member, National Institute of Diabetes & Digestive & Kidney Diseases Network of Minority Research Investigators, 2003-present
Affiliated Faculty, Center for Gene Research and Biotechnology, Oregon State University, 2004-present
Reviewer, Toxicology Letters, 2004-present
Reviewer, Medical Science Monitor, 2005- present
Rodriguez-Proteau, R., Mata, J. E., Miranda, C. L., Fan, Y., Brown, J. J., and Buhler, D. R. (2006) Plant polyphenols and multi-drug resistance: effects of dietary flavonoids on drug transporters in caco-2 cell monolayers and cell lines overexpressing MDR1. Xenobiotica, 36(1): 41–58.
Mata, J.E., Dyal, L.A., Slauson M.E., Loehr, C., Summerton J.E., Tyson, A.R., Rodriquez-Proteau, R.J., and Gustafson, S.B. (2007) Tumor imaging using technicium-99m bound to pH sensitive peptides. Nanomedicine: Nanotechnology, Biology, and Medicine, 3:297–305.
Hustace, J.L., Firshman, A.M., Mata, J.E. (2008) Pharmacokinetics and Bioavailability of Metformin in Horses. American Journal of Veterinary Research, May 2009, Vol. 70, No. 5, Pages 665-668.
Jubert, C., Mata, J., Bench, G., Dashwood, R., Pereira, C., Tracewell, W., Turteltaub, K., Williams, D., and Bailey, G. (2009) Effects of chlorophyll and chlorophyllin on low-dose aflatoxin B1 pharmacokinetics in human volunteers. Cancer Prevention. 2: 1015- 1022.+
Kuiper, H.C., Langsdorf, B.L., Miranda, C.M., Joss. J., Jubert, C., Mata, J.E., and Stevens, J.F. (2010) Quantitation of mercapturic acid conjugates of 4-hydroxy-2-nonenal and 4-oxo-2-nonenal metabolites in a smoking cessation study. Free Radical Biology & Medicine. Free Radical Biology & Medicine, 48: 65-72.
Chapters in Books
Mata, J. E., Dyal, L.A., Rossi, V.R., Gustafson, S.B. (2006) Solid Tumor Physiology as a Target for Nanomedicines, Eds. Hari Singh Nalwa and Thomas Webster in Cancer Nanotechnology – Nanomaterials for Cancer Diagnosis and Therapy. American Scientific Publishers, Valencia, CA.
Mata, J.E. (2009) “Pharmacological Considerations in the Pediatric Patient” in the new book, Small Animal Pediatrics, Michelle Kutzler and Mike Peterson, Eds., in press.
Dr. John Enrique Mata is the inventor of methods to treat cancer and polycystic kidney disease. He has taken these inventions from inception through preclinical development. In the past years he has gained experience as a pharmacologist conducting animal and human studies. An interest in the effects of natural product intervention to reduce carcinogen exposure has led to the current proposal. His experience in cancer research, toxicology and drug development provide the basis for the development of a medical countermeasure for CB threats. Previous experience with drug and medical device development, project management, team building and leadership experience will be important to the overall success of the proposed project.